REGENXBIO Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
RGNX$7.69-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Loss | Deficit | Equity | |
| Balances at December 31, 2020 | 37,476 | $4 | $667,181 | $(360) | $(289,072) | $377,753 |
| Issuance of common stock upon public offering, net of transaction costs of $14,194 | 4,899 | — | 216,059 | — | — | 216,059 |
| Exercise of stock options, net of tax | 403 | — | 4,279 | — | — | 4,279 |
| Issuance of common stock under employee stock purchase plan | 54 | — | 1,768 | — | — | 1,768 |
| Stock-based compensation expense | — | — | 38,808 | — | — | 38,808 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (2,209) | — | (2,209) |
| Net income | — | — | — | — | 127,840 | 127,840 |
| Balances at December 31, 2021 | 42,831 | 4 | 928,095 | (2,569) | (161,232) | 764,298 |
| Vesting of restricted stock units, net of tax | 60 | — | (284) | — | — | (284) |
| Exercise of stock options, net of tax | 332 | — | 2,804 | — | — | 2,804 |
| Issuance of common stock under employee stock purchase plan | 76 | — | 1,742 | — | — | 1,742 |
| Stock-based compensation expense | — | — | 40,788 | — | — | 40,788 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (12,832) | — | (12,832) |
| Net loss | — | — | — | — | (280,321) | (280,321) |
| Balances at December 31, 2022 | 43,299 | 4 | 973,145 | (15,401) | (441,553) | 516,195 |
| Vesting of restricted stock units, net of tax | 164 | — | (419) | — | — | (419) |
| Exercise of stock options, net of tax | 223 | — | 1,521 | — | — | 1,521 |
| Issuance of common stock under employee stock purchase plan | 103 | — | 1,826 | — | — | 1,826 |
| Issuance of common stock upon private placement, net of transaction costs of $126 | 257 | — | 4,874 | — | — | 4,874 |
| Stock-based compensation expense | — | — | 40,267 | — | — | 40,267 |
| Unrealized gain on available-for-sale securities, net | — | — | — | 10,972 | — | 10,972 |
| Net loss | — | — | — | — | (263,494) | (263,494) |
| Balances at December 31, 2023 | 44,046 | $4 | $1,021,214 | $(4,429) | $(705,047) | $311,742 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.